High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Background The permanent disfigurement associated with hidradenitis suppurativa (HS) necessitates early aggressive disease intervention. Although limited data support the use of infliximab (IFX) in HS, the efficacy of high-dose, high-frequency IFX has yet to be defined. Objective To evaluate the efficacy of IFX 7.5 to 10 mg/kg, with a maintenance frequency every 4 weeks. Methods Prospective analysis of 42 patients initiating IFX 7.5 mg/kg every...